Department / Division:
Medicine / Geriatrics

Address:
DUMC 3881
Durham, NC 27710

Appointment Telephone:
919-668-7630

Office Telephone:
919-660-7520

Fax Telephone:
919-684-8569

• MD, Medical College of Virginia (Virginia Commonwealth University School of Medicine), 1974

• Medicine, Medical College of Virginia, 1974-1977

• Endocrinology Metabolism, Duke University Medical Center, 1977-1979
• Geriatrics, VA Medical Center and Duke University Medical Center, 1979-1981

Clinical Interests:
Metabolic bone disease (osteoporosis, osteomalacia, Paget's disease), tumoral calcinosis, parathyroid disease, and other diseases of bone and mineral metabolism

Research Interests:
My research activities focus on understanding ways that osteoporotic fractures affect people and trying to learn ways to reduce their impact on affected individuals and prevent further fractures. I have worked with patient with hip and vertebral fractures, gaining insight into the impairments such fractures cause. Also we have learned that a hip fracture is a major risk factor for subsequent fractures after the initial hip fracture. Our group has just completed a randomized, placebo-controlled trial that we designed with Novartis Pharmaceutical Corporation showing, that an annual infusion of a 5mg of the bisphosphonate zoledronic acid reduced subsequent fractures after a surgical procedure for a hip fracture by 35% when compared to a place infusion (New England Journal of Medicine, 1-1-07). In this study we also observed a 28% reduction in death in the zoledronic acid treated patients. Our group continues to analyze data from this study.

In other work, our group tries to understand how other diseases such as strokes and spinal cord injury, and medications such as anticonvulsants place patients at risk for fractures. As we understand the epidemiology of these types of fractures, we plan to develop intervention trials to test whether we can reduce the occurrence of these fractures.

In addition to the above described work our group has help design and conduct a number of phase 1,2 and 3 clinical trials in Paget's disease of Bone and osteoporosis.


KEY WORDS:
Oteoporosis
Hip and vertebra fractures
Paget's disease of bone
Mobility impairments from metabolic bone diseases

Representative Publications:
2) Lyles KW, Jackson TW, Nesbitt T, Quarles D: Salomon Calcitonin Reduces Vertebral Bone Loss in Glucocorticoid Treated Dogs. Am. J. Physiology, Vol. 294, No. 6, E938-E942, 1993. (1993)

1) Lyles KW, Gold DT, Shipp KM, Pieper CF, Martinez S, Mulhausen PL: Osteoporotic Vertebral Compression Fractures: Their Association with Impaired Functional Status. American Journal of Medicine, Vol. 94, No.6, 595-601, 1993. (1993)

5) Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK: Healing of Bone Disease in X-Linked Hypophosphatemic Rickets/Osteomalacia: Introduction and Maintenance with Phosphorus and Calcitriol. Journal of Clinical Investigation, Vol. 75, 1858-1868, 1985. (1985)

3) Lyles KW, Burkes EJ, Ellis GJ, Lucas KJ, Dolan EA and Drezner MK: Genetic Transmission of Tumoral Calcinosis: Autosomal Dominat with Variable Clinical Expressivity. Journal of Clinical Endocrinology and Metabolism, Vol. 60, No. 6, 1093-1096, 1985. (1985)

4) Lyles KW, Berry WB, Harrelson JM, Haussler MR, and Drezner MK: Hypophosphatemic Osteomalacia: Association with Prostatic Carcinoma. Annals of Internal Medicine, Vol. 93, No. 2, 275-278, 1980. (1980)